Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Two-Part (Open-Label Followed by Randomized, Double-Blind, Placebo-Controlled) Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of Topically Administered LUT014 for the Treatment of Radiation-Induced Dermatitis in Breast Cancer Patients

Next Previous
Trial Profile

A Two-Part (Open-Label Followed by Randomized, Double-Blind, Placebo-Controlled) Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of Topically Administered LUT014 for the Treatment of Radiation-Induced Dermatitis in Breast Cancer Patients

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 23 Feb 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs LUT 014 (Primary)
  • Indications Radiodermatitis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Lutris Pharma

Most Recent Events

  • 21 Feb 2024 According to a Lutris Pharma Media Release, results from this study were published in the peer-reviewed, JAAD International, in an article entitled, "A Topical BRAF Inhibitor (LUT014) For Treatment of Radiodermatitis Among Women with Breast Cancer."
  • 21 Feb 2024 Results presented in a Lutris Pharma Media Release.
  • 07 Sep 2022 Results from open label part 1 and double blinded part 2 of this trial published in the Lutris Pharma Media Release

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top